|
| Press Releases |
|
 |
|
| Tuesday, April 22, 2025 |
|
|
Everest Medicines Announces Approval of 'B' Marker Removal from Company's Stock Code by the Hong Kong Stock Exchange |
| Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that The Stock Exchange of Hong Kong Limited (the 'Stock Exchange') has approved the Company's application to remove the "B" marker from its stock short name, as the company has satisfied the requirements of the listing rules at the Stock Exchange. more info >> |
|
|
雲頂新耀「摘B」成功 盈利能力與創新價值獲雙重驗證 |
| 今日，雲頂新耀（HKEX 1952.HK）宣佈公司已獲香港聯交所批准，將「B」標記從股票代碼中移除 more info >> |
|
|
云顶新耀"摘B"成功 盈利能力与创新价值获双重验证 |
| 今日，云顶新耀（HKEX 1952.HK）宣布公司已获香港联交所批准，将"B"标记从股票代码中移除。 more info >> |
|
| Wednesday, March 19, 2025 |
|
|
雲頂新耀啟動嘉善工廠伊曲莫德生產建設項目 加速本地化供應佈局 |
| 今日，雲頂新耀宣佈正式啟動伊曲莫德（VELSIPITY(R)）位於嘉善工廠的生產建設項目，以支持該藥物的本地化生產，進一步滿足中國及亞洲市場對潰瘍性結腸炎（UC）治療的需求。該項目總投資達7000萬元，預計投產後年產能可達5000萬片，供應範圍涵蓋中國大陸、中國香港、中國澳門、中國台灣、韓國及新加坡等市場。 more info >> |
|
|
云顶新耀启动嘉善工厂伊曲莫德生产建设项目 加速本地化供应布局 |
| 今日，云顶新耀宣布正式启动伊曲莫德（VELSIPITY(R)）位于嘉善工厂的生产建设项目，以支持该药物的本地化生产，进一步满足中国及亚洲市场对溃疡性结肠炎（UC）治疗的需求。该项目总投资达7000万元，预计投产后年产能可达5000万片，供应范围涵盖中国大陆、中国香港、中国澳门、中国台湾、韩国及新加坡等市场。 more info >> |
|
| Monday, March 10, 2025 |
|
|
雲頂新耀「AI+創新藥」第一股成港股18A黑馬 |
| 近年來，AI賦能創新藥研發已成為全球生物醫藥行業的重要趨勢，尤其在mRNA疫苗領域，AI更是成為提升研發效率與精准度的核心驅動力。 more info >> |
|
|
云顶新耀"AI+创新药"第一股成港股18A黑马 |
| 近年来，AI赋能创新药研发已成为全球生物医药行业的重要趋势，尤其在mRNA疫苗领域，AI更是成为提升研发效率与精准度的核心驱动力。 more info >> |
|
| Friday, March 7, 2025 |
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation |
| Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock had risen 20.12% to HK$60.6, bringing the company's total market capitalization to HK$19.791 billion. more info >> |
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值 |
| 今日，雲頂新耀（1952.HK）股價強勢上漲，高開後持續走強，全天維持上升趨勢，截至收盤上漲20.12%，報60.6港元，公司總市值攀升至197.91億港元。創下自2021年9月28日以來的近三年半新高，並成功突破2020年IPO發行價55港元。 more info >> |
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值 |
| 今日，云顶新耀（1952.HK）股价强势上涨，高开后持续走强，全天维持上升趋势，截至收盘上涨20.12%，报60.6港元，公司总市值攀升至197.91亿港元。创下自2021年9月28日以来的近三年半新高，并成功突破2020年IPO发行价55港元。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
潼關黃金獲納入MSCI全球小型股指數 資本市場影響力進一步提升
Aug 13, 2025 19:19 HKT/SGT
|
|
|
Intellifusion Submits an Application to List on the Hong Kong Stock Exchange: A National Breakthrough in AI Inference Chips
Aug 13, 2025 18:33 HKT/SGT
|
|
|
Kangji Medical Receives Privatisation Proposal from a Consortium Led by Kangji Medical's Chairman, Zhong Ming, TPG and QIA to Advance Long-Term Strategic Vision
Aug 13, 2025 15:33 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 13, 2025 15:05 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 13, 2025 14:53 HKT/SGT
|
|
|
GEON Performance Solutions Achieves Great Place to Work Recognition Globally Second Year in a Row
Aug 13, 2025 14:18 HKT/SGT
|
|
|
China Lilang Announces 2025 Interim Results
Aug 13, 2025 14:15 HKT/SGT
|
|
|
Natural Beauty 2025 Interim Profit Surges by 136% to HK$11 Million
Aug 13, 2025 14:13 HKT/SGT
|
|
|
AsiaMedic Reports 26% Revenue Growth to S$16.6 million in 1H2025, Led by Strong Diagnostic Imaging Performance
Aug 13, 2025 14:00 HKT/SGT
|
|
|
74th China (Linyi) International Hardware Expo to Open September 5-7, 2025 in Shandong
Aug 13, 2025 12:00 HKT/SGT
|
|
|
AI Inference vs. AI Training: What Are the Differences?
Aug 13, 2025 11:00 HKT/SGT
|
|
|
Shoucheng Joins World Humanoid Robot Games - 88 Spectators Invited
Aug 13, 2025 10:15 HKT/SGT
|
|
|
首程控股(0697.HK)抽取88位幸運觀眾現場觀賽 深度參與世界人形機器人運動會
Aug 13, 2025 09:58 HKT/SGT
|
|
|
首程控股(0697.HK)抽取88位幸运观众现场观赛 深度参与世界人形机器人运动会
Aug 13, 2025 09:43 HKT/SGT
|
|
|
康基醫療收到由董事長鍾鳴、TPG及卡塔爾投資局(QIA)牽頭財團提出之私有化要約 助力公司實現長遠願景
Aug 13, 2025 09:27 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
